Attenuation of Follicular Helper T Cell–Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome

Arthritis and Rheumatology

Volumn 69, Issue 9, 2017, Pages 1850-1861

  Verstappen, Gwenny M ^a   Meiners, Petra M ^a   Corneth, Odilia B J ^b   Visser, Annie ^a   Arends, Suzanne ^a   Abdulahad, Wayel H ^a   Hendriks, Rudi W ^b   Vissink, Arjan ^a   Kroese, Frans G M ^a   Bootsma, Hendrika ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 21; LA ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; RO ANTIBODY; CXCL13 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN DERIVATIVE;

ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; EFFECTOR CELL; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY TEST; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; OPEN STUDY; PAROTID GLAND; PLASMABLAST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SJOEGREN SYNDROME; SYSTEMIC DISEASE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TFH CELL; TH1 CELL LINE; TH17 CELL; TH2 CELL; TREATMENT OUTCOME; ADULT; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; HELPER CELL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PLASMA CELL; SJOGREN'S SYNDROME;

ABATACEPT; ADULT; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CXCL13; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PLASMA CELLS; PROSPECTIVE STUDIES; SJOGREN'S SYNDROME; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 85028446601     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40165     Document Type: Article

References (50)

1. Fox RI. Sjögren's syndrome. Lancet 2005;366:321–31.
2. Kroese FG, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H. B-cell hyperactivity in primary Sjögren's syndrome. Expert Rev Clin Immunol 2014;10:483–99.
3. Corneth OB, Verstappen GM, Paulissen SM, de Bruijn MJ, Rip J, Lukkes M, et al. Enhanced Bruton's tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease. Arthritis Rheumatol 2017;69:1313–24.
4. + T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 2013;39:770–81.
5. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity 2014;41:529–42.
6. Simpson N, Gatenby PA, Wilson A, Malik S, Fulcher DA, Tangye SG, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010;62:234–44.
7. + memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013;39:758–69.
8. Vinuesa CG, Cook MC. Blood relatives of follicular helper T cells. Immunity 2011;34:10–2.
9. Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 2017;542:110–4.
10. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765–2.
11. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999;397:263–6.
12. Moens L, Tangye SG. Cytokine-mediated regulation of plasma cell generation: IL-21 takes center stage. Front Immunol 2014;5:65.
13. Kang KY, Kim HY, Kwok SK, Ju JH, Park KS, Sun DI, et al. Impact of interleukin-21 in the pathogenesis of primary Sjögren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther 2011;13:R179.
14. Liu R, Su D, Zhou M, Feng X, Li X, Sun L. Umbilical cord mesenchymal stem cells inhibit the differentiation of circulating T follicular helper cells in patients with primary Sjögren's syndrome through the secretion of indoleamine 2,3-dioxygenase. Rheumatology (Oxford) 2015;54:332–42.
15. Gong YZ, Nititham J, Taylor K, Miceli-Richard C, Sordet C, Wachsmann D, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren's syndrome. J Autoimmun 2014;51:57–66.
16. Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov 2014;13:379–95.
17. Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009;229:307–21.
18. Ndejembi MP, Teijaro JR, Patke DS, Bingaman AW, Chandok MR, Azimzadeh A, et al. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006;177:7698–706.
19. Patakas A, Ji RR, Weir W, Connolly SE, Benson RA, Nadler SG, et al. Abatacept inhibition of T cell priming in mice by induction of a unique transcriptional profile that reduces their ability to activate antigen-presenting cells. Arthritis Rheumatol 2016;68:627–38.
20. Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, et al. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 2014;73:1393–6.
21. Adler S, Körner M, Förger F, Huscher D, Caversaccio MD, Villiger PM. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren's syndrome: a pilot study. Arthritis Care Res (Hoboken) 2013;65:1862–8.
22. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8.
23. Land J, Abdulahad WH, Sanders JS, Stegeman CA, Heeringa P, Rutgers A, et al. Regulatory and effector B cell cytokine production in patients with relapsing granulomatosis with polyangiitis. Arthritis Res Ther 2016;18:84.
24. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010;69:1103–9.
25. Seror R, Meiners P, Baron G, Bootsma H, Bowman SJ, Vitali C, et al. Development of the ClinESSDAI: a clinical score without biological domain: a tool for biological studies. Ann Rheum Dis 2016;75:1945–50.
26. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708–12.
27. Twisk JW. Longitudinal data analysis: a comparison between generalized estimating equations and random coefficient analysis. Eur J Epidemiol 2004;19:769–76.
28. Mingueneau M, Boudaoud S, Haskett S, Reynolds TL, Nocturne G, Norton E, et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol 2016;137:1809–21.e12.
29. Boesteanu AC, Katsikis PD. Memory T cells need CD28 costimulation to remember. Semin Immunol 2009;21:69–77.
30. Verstappen GM, Kroese FG, Meiners PM, Corneth OB, Huitema MG, Haacke EA, et al. B cell depletion therapy normalizes circulating follicular Th cells in primary Sjögren syndrome. J Rheumatol 2017;44:49–58.
31. Haacke EA, van der Vegt B, Meiners PM, Vissink A, Spijkervet FK, Bootsma H, et al. Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue. Clin Exp Rheumatol 2017;35:317–20.
32. Szabo K, Papp G, Barath S, Gyimesi E, Szanto A, Zeher M. Follicular helper T cells may play an important role in the severity of primary Sjögren's syndrome. Clin Immunol 2013;147:95–104.
33. Choi YS, Kageyama R, Eto D, Escobar TC, Johnston RJ, Monticelli L, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 2011;34:932–46.
34. Chevalier N, Jarrossay D, Ho E, Avery DT, Ma CS, Yu D, et al. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol 2011;186:5556–68.
35. Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999;402:827–32.
36. Gigoux M, Shang J, Pak Y, Xu M, Choe J, Mak TW, et al. Inducible costimulator promotes helper T-cell differentiation through phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2009;106:20371–6.
37. Corneth OB, de Bruijn MJ, Rip J, Asmawidjaja PS, Kil LP, Hendriks RW. Enhanced expression of Bruton's tyrosine kinase in B cells drives systemic autoimmunity by disrupting T cell homeostasis. J Immunol 2016;197:58–67.
38. Weber JP, Fuhrmann F, Feist RK, Lahmann A, Al Baz MS, Gentz LJ, et al. ICOS maintains the T follicular helper cell phenotype by down-regulating Krüppel-like factor 2. J Exp Med 2015;212:217–33.
39. Pratama A, Srivastava M, Williams NJ, Papa I, Lee SK, Dinh XT, et al. MicroRNA-146a regulates ICOS-ICOSL signalling to limit accumulation of T follicular helper cells and germinal centres. Nat Commun 2015;6:6436.
40. Iwata S, Nakayamada S, Fukuyo S, Kubo S, Yunoue N, Wang SP, et al. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. Arthritis Rheumatol 2015;67:63–73.
41. Platt AM, Gibson VB, Patakas A, Benson RA, Nadler SG, Brewer JM, et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010;185:1558–67.
42. Scarsi M, Paolini L, Ricotta D, Pedrini A, Piantoni S, Caimi L, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol 2014;41:666–72.
43. Rozanski CH, Arens R, Carlson LM, Nair J, Boise LH, Chanan-Khan AA, et al. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med 2011;208:1435–46.
44. Mei HE, Wirries I, Frölich D, Brisslert M, Giesecke C, Grün JR, et al. A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. Blood 2015;125:1739–48.
45. Lindop R, Arentz G, Bastian I, Whyte AF, Thurgood LA, Chataway TK, et al. Long-term Ro60 humoral autoimmunity in primary Sjögren's syndrome is maintained by rapid clonal turnover. Clin Immunol 2013;148:27–34.
46. Golovina TN, Mikheeva T, Suhoski MM, Aqui NA, Tai VC, Shan X, et al. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008;181:2855–68.
47. Szabo K, Papp G, Dezso B, Zeher M. The histopathology of labial salivary glands in primary Sjögren's syndrome: focusing on follicular helper T cells in the inflammatory infiltrates. Mediators Inflamm 2014; 2014:631787.
48. Haskett S, Ding J, Zhang W, Thai A, Cullen P, Xu S, et al. Identification of novel CD4 + T cell subsets in the target tissue of Sjögren's syndrome and their differential regulation by the lymphotoxin/LIGHT signaling axis. J Immunol 2016;197:3806–19.
49. Ramos-Casals M, Brito-Zeron P, Solans R, Camps MT, Casanovas A, Sopena B, et al. Systemic involvement in primary Sjögren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 2014;53:321–31.
50. Nocturne G, Seror R, Fogel O, Belkhir R, Boudaoud S, Saraux A, et al. CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sjögren's syndrome. Arthritis Rheumatol 2015;67:3226–33.